Myocardial damage in multisystem inflammatory syndrome associated with COVID-19 in children and adolescents

Vladislav Vukomanovic1,2, Stasa Krasic1, Sergei Prijic1,2, Gordana Petrovic3, Sanja Ninic1, Sasa Popovic1, Ivana Cerovic1, Snezana Ristic4, Dejan Nestic5

1Department of Cardiology, Mother and Child Health Institute of Serbia, Belgrade, Serbia, 2School of Medicine, University of Belgrade, Belgrade, Serbia, 3Department of Immunology, Mother and Child Health Institute of Serbia, Belgrade, Serbia, 4Intensive Care Unit, Mother and Child Health Institute of Serbia, Belgrade, Serbia, 5Institute of Medical Physiology “Rihard Bunari”, Belgrade, Serbia

Background: In multisystem inflammatory syndrome in children (MIS-C) temporarily associated with coronavirus disease-19 (COVID-19), myocardial damage has been reported. Materials and Methods: A retrospective observational cohort study included children under 18 who had a myocardial injury related to COVID-19 treated in mother and child health institute from April 2020 to August 2020. Myocardial injury related to COVID-19 was manifested by elevated serum cardiac troponin and NT-proBNP with LV dysfunction, arrhythmias, and coronary arteries (CAs) dilatation or aneurysms. During the short-term follow-up, cardiac testing (electrocardiography, laboratory analysis, echocardiography, 24-h Holter monitoring, exercise stress test, and cardiac magnetic resonance) was performed. Results: Six male adolescents (14.7 ± 2.4 years) were included in the analysis (2/6 had MIS-C shock syndrome). All patients had elevated acute-phase reactants and NT-proBNP, whereas troponins were elevated in 5/6 patients. Echocardiography revealed left ventricular (LV) systolic dysfunction (EF 45.2 ± 6.9%); 2/6 had dilated CAs. IVIG was prescribed to all patients with MIS-C. Four patients required inotropic drug support. During hospitalization, a significant reduction of CRP, LDH, NT-proBNP, and D-dimer (P < 0.05) was registered. LV systolic function recovery was registered 3 days after applied therapy (P < 0.001). None of the patients developed dilated cardiomyopathy or CA aneurysms. Conclusions: With early recognition and adequate MIS-C therapy, children recovered entirely, maintained in the short-term follow-up period.

INTRODUCTION

Multisystem inflammatory syndrome in children (MIS-C) temporarily associated with the coronavirus disease-19 (COVID-19) is sporadically presented after an infection caused by a novel coronavirus (SARS-CoV-2).[1-4] These pediatric cases’ clinical features are similar to the previously described inflammatory syndromes such as viral myocarditis, Kawasaki disease (KD), KD shock syndrome, and toxic shock syndrome.[5] MIS-C was defined as acute febrile state lasting at least 24 hours with elevated inflammatory markers, and the existence of the following criteria: (1) clinically severe illness requiring hospitalization and two or more organ involvement and (2) positive serology, reverse transcription-polymerase chain reaction (RT-PCR), or antigen test; or COVID-19 exposure within the past 4 weeks before symptom onset.[7] Many children with MIS-C had positive antibodies to SARS-CoV-2, but negative RT-PCR test because MIS-C typically manifests 3–6 weeks after SARS-CoV-2 infection.[1,5-8] The delay in presentation proposes that this inflammatory syndrome is postponed immune responses on SARS-CoV-2.[2]
Our work analysed cardiovascular findings in MIS-C concerning premorbidity status, incubation period, laboratory characteristics, diagnostics methods, treatment and outcome of diseases.

**MATERIALS AND METHODS**

A retrospective observational cohort study included children under 18 years who had a myocardial injury related to COVID-19 treated in Mother and child health Institute of Serbia from April 2020 to August 2020. Myocardial injury related to COVID-19 was manifested by elevated serum cardiac troponin (cTn) and NT-proBNP with left ventricle (LV) dysfunction, arrhythmias, and coronary arteries (CAs) dilatation or aneurysms. In all patients, PCR to detect cardiotropic viral nucleic acid in the blood was performed. In all patients, serological examination for SARS-CoV-2 was done. Laboratory analyses, electrocardiography (ECG), X-ray, and echocardiographic examination were performed at the admission, the 3rd, the 7th day of in-hospital stay, and the discharge. Patients with MIS-C were treated according to the standard protocols.

During the short-term follow-up, cardiac testing (ECG, laboratory analysis, echocardiography, 24-h Holter monitoring, exercise stress test, and cardiac magnetic resonance) was performed. If cardiac testing has normalized, we advised to athletes gradually increase physical activity.

The study was approved by the institutional ethical committee (reference number 2099/1).

**RESULTS**

Our study included six male adolescents; the average years of age were 14.7 ± 2.4. They had a history of fever (6/6), fatigue (3/6), headache (3/6), gastrointestinal manifestations (abdominal pain, vomiting, and diarrhea (4/6), and thoracic pain (1/6). The fever with gastrointestinal manifestations lasted 5 days, before the myocardial injury was established. Polymorph cutaneous rash, bilateral (nonexudative) conjunctivitis, and conjunctival suffusion had 5/6 patients. Systemic hypotension and oliguria were registered in two patients. Two patients had SARS-CoV-2 exposure 4 weeks before symptom onset. Diagnosis of MIS-C was made in 6 adolescents, whereas MIS-C shock syndrome had 2/6.

RT-PCR for SARS-CoV-2 was positive in one patient; the other had positive SARS-CoV-2-specific neutralizing antibody. In two patients, cytomegalovirus (CMV) and Epstein–Barr virus (EBV) were isolated from blood samples. Laboratory analysis at the admission is shown in Table 1.

The X-ray showed an enlarged heart shadow in 3/6. A prolonged QTc interval was observed in all patients with MIS-C in the recovery period. All echocardiography parameters are presented in Table 2. Two patients with MIS-C had mildly dilated CAs.

The patients were treated with IVIG (5/6), corticosteroids (3/6), and vasoactive and inotropic drugs (6/6).

Laboratory analysis and the difference between their average values measured in the 3rd and the 7th day of in-hospital stay and at discharge are presented in Table 1. By comparing the difference between laboratory parameters at the admission and discharge, a significant reduction of LDH, D-dimers, and NT-proBNP was observed [Figure 1].

### Table 1: Laboratory parameters of our patients

|                      | Admission | 3rd day | 7th day | Discharge | P       |
|----------------------|-----------|---------|---------|-----------|---------|
| CRP (mg/l)           | Median: 136 IQR: 95.6-210.7 | 121.2 IQR: 77.9-186.2 | 48.7 IQR: 23.8-77.5 | 2.45 IQR: 1.3-5.5 | <0.05^†,‡ |
| WBC (10^3)           | Median: 11.25 IQR: 6.7-14.6 | 9.8 IQR: 7.8-15.3 | 9.5 IQR: 7.8-15.1 | 6.76 IQR: 5.4-13.7 | >0.05 |
| Hemoglobin (g/l)     | Median: 125.5 IQR: 118.2-142.5 | 123.5 IQR: 106.7-127.5 | 128 IQR: 111.5-135.5 | 136 IQR: 121.5-144.5 | >0.05 |
| Platelets (10^5)     | Median: 121 IQR: 96.7-166.5 | 156 IQR: 95.2-214.5 | 334 IQR: 149-484 | 422.5 IQR: 282.2-505.2 | <0.05^†,‡ |
| Albumin (g/l)        | Median: 37.5 IQR: 30.7-41 | 29.5 IQR: 27.5-37.2 | 27 IQR: 26.5-35 | 38.5 IQR: 37.7-41.5 | 0.02^† |
| Na (mmol/l)          | Median: 133 IQR: 132.5-137 | 135 IQR: 131.2-138.2 | 136 IQR: 134-139.5 | 136 IQR: 132.5-139.2 | >0.05 |
| Cr (μmol/l)          | Median: 81 IQR: 62-117.5 | 68.5 IQR: 54-88.5 | 61 IQR: 52-78.5 | 55.5 IQR: 51-63.25 | 0.04^† |
| ALT (I/L/L)          | Median: 43.5 IQR: 18-82.7 | 27 IQR: 13-27 | 54 IQR: 32.5-103.5 | 38.5 IQR: 22.5-88.7 | >0.05 |
| LDH (I/L/L)          | Median: 462 IQR: 355.5-617.7 | 338.5 IQR: 303-504.5 | 394 IQR: 295.7-504.2 | 317.5 IQR: 293.7-364.7 | 0.02^† |
| D-dimer (ng/ml)      | Median: 906 IQR: 510-2052 | 607 IQR: 264-1447 | 327.5 IQR: 107-327.5 | 176 IQR: 104.5-283.5 | 0.04^† |
| cTnI (ng/ml)         | Median: 1.5 IQR: 0.05-3.9 | 0.37 IQR: 0.05-2.5 | 0.05 IQR: 0.05-1.92 | 0.05 IQR: 0.05-0.05 | 0.05^† |
| NT-proBNP (pg/ml)    | Median: 4368 IQR: 1446.5-5000 | 2987 IQR: 507.5-5000 | 14.45 IQR: 399.5-4154 | 41.5 IQR: 30-212.2 | 0.02^† |
| Feritin (ug/l)       | Median: 1288 IQR: 300-1288 | 559.2 IQR: 184.8-559.2 | 537 IQR: 182-537 | 266.5 IQR: 161.5-451.7 | <0.001^† |
| Procalcitonin (ng/ml)| Median: 4.04 IQR: 0.67-4.04 | 0.73 IQR: 0.07-0.73 | - IQR: - | 0.08 IQR: 0.02-0.08 | <0.001^† |

*Difference between values at the admission and the 3rd day; †Admission to 7th day; ‡Admission to discharge. CRP=C-reactive protein; WBC=White blood cell; Hgb=Hemoglobin; Na=Sodium; Cr=Creatinine; ALT=Alanine transaminase; LDH=Lactate dehydrogenase; cTnI=Cardiac troponin I; NT-proBNP=N-terminal pro hormone B-type natriuretic peptide; IQR=Interquartile range
All echocardiographic parameters are presented in Table 2. A significant improvement of LV systolic function was observed on day 3 [Figure 1]. Echocardiography examination after discharge was normal in all patients.

In the short-term (4.2 ± 2.0 months) follow-up period, all patients had normal laboratory parameters, LV systolic, and diastolic function with appropriate CA diameter; none developed dilated cardiomyopathy. On the ECG, 24-h Holter monitor, rhythm, and conduction disturbances were not observed in all patients. The fatal outcome did not observe.

**DISCUSSION**

A limited number of predisposing children could develop MIS-C temporally associated with SARS-CoV-2 infection. Unsteady clinical presentations in children open the question is it entirely different etiology, or in epigenetically responsive individuals, the virus can initiate some pathophysiological pathways with the consequent clinical presentation of MIS-C.[3,9] In two patients, EBV and CMV were detected in the blood samples, but those patients also had antibodies against SARS-CoV-2. KD-like clinical presentation, gastrointestinal symptoms, laboratory analyses, and echocardiography finding in these patients refer more to MIS-C than acute infection caused by these two viruses. However, both viruses could be associated with KD in children under the age of 5, because most adolescents and adults have developed protective immunity on EBV and CMV.[10-12] In addition, HIV is the most frequently reported infectious disease associated with KD in adults’ rare cases.[12] Although MIS-C has overlapping features with KD, our patients with MIS-C were adolescents with frequent gastrointestinal and cardiovascular symptoms.

The predominance of cardiac damage in MIS-C (over 80% of patients) was striking.[9,13,14] Cardiomyocyte necrosis in children with COVID-19 might be caused by direct viral acting on ACE-2 receptors or indirect injury due to cytokine releasing or ischemia.[3,9] All patients had a myocardial injury, but two patients had MIS-C shock syndrome with sustained hypotension and clinical signs of low cardiac output with the need for inotropic drug support. In 60.2%–82% of children, MIS-C shock syndrome was observed.[3] Our patients with MIS-C had prolonged QTc, and it might be a result of inflammation and change ion channels activity (especially K+ and Ca2+ channels-inflammatory cardiac channelopathies).[13]

The most current cardiac abnormality on the echocardiogram was a depressed EF, FS, pericardial effusion, and mitral regurgitation.[1,3] Echocardiography showed LV systolic impairment at the admission, but significant improvement was observed on the 3rd hospital day. Those findings combined with a significant reduction of cardiomyocytolysis markers and NT-proBNP on the 3rd hospital day refers to possible indirect myocardial injury. Ectasias of CAs had 2/6 cases, but diameters were appropriate at the discharge. In <20% of the patients, the CA’s mild dilatation without segmental aneurysms was described.[9,14]

The resemblance between KD and MIS-C suggests that they may share similar pathophysiology, with the possibility to respond on similar drugs.[3] One of the patients with MIS-C shock syndrome did not respond to IVIG-treatment, so he was treated according to the refractory KD protocol. Children with KD-like during the SARS-CoV-2 pandemic were more common unresponsive to IVIG-treatment than children with classic KD.[15]

In patients with MIC-S, the mortality rate was 1.7%. [3] We did not observe the fatal outcome and fulminant myocarditis. None of the patients during the short-term follow-up developed dilated cardiomyopathy and CAs aneurysms.

**CONCLUSION**

MIS-C is a life-threatening state distinguished by excessive inflammation, consequent fever, abdominal symptoms, conjunctivitis, rash, and myocardial injury. Children

---

**Table 2: Echocardiography parameters of our patients**

|                | Admission Mean±SD (minimum-maximum) | Z-score | Third day Mean±SD (minimum-maximum) | Z-score | Discharge Mean±SD (minimum-maximum) | Z-score | P      |
|----------------|------------------------------------|---------|-------------------------------------|---------|-------------------------------------|---------|--------|
| LV EDD (mm)    | 52.8±3.41 (48-57)                  | 0.5±0.9 | 53.7±3.98 (49-61)                   | 0.7±1.1 | 47.6±4.8 (39-52)                   | 0.0±0.9 | 0.02†  |
| LV ESD (mm)    | 39.0±3.65 (35-43)                  | 2.2±1.19| 36.0±2.65 (32-39)                  | 0.99±1.2 | 31.1±2.9 (27-35)                   | 0.2±0.7 | 0.04†  |
| IVSd (mm)      | 10.4±0.9 (9-11)                    | 1.21±0.5| 10.6±1.2 (9-12)                    | 1.14±0.5 | 10.6±0.7 (9.5-11)                  | 0.3±0.5 | >0.05 (z-score) |
| PWd (mm)       | 9.6±0.9 (8-10)                     | 1.29±0.76| 10.2±0.8 (9-11)                   | 1.44±0.71| 10±0.6 (9-11)                     | 1.5±0.7 | >0.05 (z-score) |
| LCA (mm)       | 4.25±0.9 (3-5)                     | 0.96±1.66| 3.5±0.7 (3-4)                     | 0.4±1.11 | 2.83±0.7 (2-3.5)                  | -0.7±1.66| >0.05 (z-score) |
| RCA (mm)       | 3.5±0.9 (3-4.5)                    | 0.90±1.21| 3 (3-3)                            | -0.3±0.14| 2.4±0.5 (2-3)                     | 1.7±1.22| >0.05 (z-score) |
| LV EF (%)      | 45.2±6.9 (37-55)                   | -       | 60.8±6.5 (50-68)                  | -       | 67.2±4.9 (60-74)                  | -       | <0.001†  |
| LV FS (%)      | 21.25±2.5 (18-24)                  | -       | 32.8±5.5 (25-39)                   | -       | 36.38±3.12 (34-40)                | -       | <0.05†  |

†Difference between values at the admission to 3rd day; ‡Admission to discharge. LV=Left ventricle; EDD=End-diastolic diameter; ESD=End-systolic diameter; IVSd=Interventricular septum diastolic diameter; PWd=Posterior wall diastolic diameter; LCA=Left coronary artery; RCA=Right coronary artery; EF=Ejection fraction; FS=Fractional shortening; SD=Standard deviation
typically developed MIS-C after SARS-CoV-2 infection, and in most cases, only antibodies against SARS-CoV-2 were funded in serum. MIS-C can progress rapidly into shock. Rapid normalization of cardiomycytolysis markers and echocardiography parameters refer to possible indirect myocardial injury. Early recognition and adequate treatment enable children survival without complications in the short-term follow-up period.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**REFERENCES**

1. Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine 2020;26:100527.
2. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020;20:e276-88.
3. Levin M. Childhood multisystem inflammatory syndrome – A new challenge in the pandemic. N Engl J Med 2020;383:393-5.
4. Abrams JY, Godfred-Cato SE, Oster ME, Chow EJ, Koumans EH, Bryant B, et al. Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2: A systematic review. J Pediatr 2020;5:226:45-54.e1.
5. Matsubara D, Kaufman HL, Wang Y, Calderon-Anyosa R, Nadaraj S, Elias MD, et al. Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19.
in the United States. J Am Coll Cardiol 2020;76:1947-61.
6. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: A systematic review. JAMA Pediatr 2020;174:882-9.
7. Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome; 2020. Available from: https://www.cdc.gov/mis-c/hcp/(). [Last accessed on 2020 Aug 19].
8. The Royal College of Paediatrics and Child Health. Guidance – Paediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19 (PIMS); 2020. Available from: https://www.rcpch.ac.uk/resources/guidance‑paediatric‑multisysteminflammatory‑syndrome‑temporally‑associated‑covid‑19‑pims. [Last accessed on 2020 Aug 19].
9. Dolhnikoff M, Ferreira Ferranti J, de Almeida Monteiro RA, Duarte-Neto AN, Soares Gomes-Gouvêa M, Viu Degaspare N, et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome. Lancet Child Adolesc Health 2020;4:790-4.
10. Rosenfeld N, Tasher D, Ovadia A, Abiri S, Dalal I. Kawasaki disease with a concomitant primary Epstein – Barr virus infection. Pediatr Rheumatol Online J 2020;18:65.
11. Usta Guc B, Cengiz N, Yildirim SV, Uslu Y. Cytomegalovirus infection in a patient with atypical Kawasaki disease. Rheumatol Int 2008;28:387-9.
12. Cunha BA, Pherez FM, Alexiadis V, Gagos M, Strollo S. Adult Kawasaki’s disease with myocarditis, splenomegaly, and highly elevated serum ferritin levels. Heart Lung 2010;39:164-72.
13. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study. Lancet 2020;395:1771-8.
14. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020;142:429-36.
15. Merino JL, Martinez-Cossiani M, Iniesta A, Escobar C, Rey JR, Castrejón-Castrejón S. COVID-19 and QT interval prolongation: More than just drug toxicity? Europace 2020;22:1479.